Patients were predominantly female and white
Most of the observational studies also show that the mutation in the GIP receptor causing decreased receptor signaling leads to lowering the bone mineral density (BMD) and increased further risk
Enfin, la grande mta-analyse en rseau de Shi et al
The inactive structure aligns with the dual functional hypothesis of the ECD through which, on one hand, peptide binding and activation is mediated when the ligand is present, while on the other, the receptor is negatively regulated in its peptide-free state
TRIUMPH-4 Phase III: 28.7% weight loss at 68 weeks highest ever recorded.Retatrutide vs Semaglutide vs TirzepatideRetatrutide: 28.7% weight loss (68 wk) Triple agonist (GLP-1+GIP+GCGR)Tirzepatide (Mounjaro/Zepbound): 22.5% (72 wk) Dual agonist (GLP-1+GIP)Semaglutide (Wegovy/Ozempic): 15-17% (68 wk) GLP-1 onlyKey Clinical Results (April 2026)TRIUMPH-4 Phase III (Dec 2025): 28.7% body weight reduction, 71.2 lbs lost at 12mg doseTRANSCEND-T2D-1 (Mar 2026): 2.0% HbA1c reduction, 16.8% weight loss in type 2 diabetesPhase II (NEJM 2023): 24.2% weight loss at 48 weeks, no plateau observedFDA NDA submission: Q4 2026-Q1 2027Research-Grade RetatrutideBioInfinity Lab GLP3-R: 99%+ purity, third-party COA verified, GMP compliant
The bull case: the platform is resilient and can pivot User base and brand value: the company has proven it can acquire and retain subscribers at low cost
